Manufacturer
KRKA
Contents
Pantoprazole Na sesquihydrate
Indication
Moderate & severe reflux oesophagitis, gastric & duodenal ulcer, Zollinger-Ellison syndrome & other gastric acid hypersecretory states. Combination therapy for eradication of Helicobacter pylori in patients w/ peptic ulcer for the prevention of duodenal & gastric ulcer relapse.
Instruction
Reduced absorption of ketoconazole. Changes in INR w/ phenprocoumon or warfarin
Drug interaction
Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time of warfarin. May increase serum concentration of methotrexate and saquinavir. Delayed absorption and decreased bioavailability w/ sucralfate. Decreased absorption of ketoconazole, itraconazole.
Potentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine, atazanavir and nelfinavir.
Malaysia
